Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tremelimumab |
Synonyms | |
Therapy Description |
Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tremelimumab | Imjudo | CP-675,206|Ticilimumab|CP-675206 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Imjudo (tremelimumab) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937). Imjudo (tremelimumab) is FDA approved for use in combination with Imfinzi (durvalumab) in adult patients with unresectable hepatocellular carcinoma, and in combination with Imfinzi (durvalumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02537418 | Phase I | Cisplatin + Etoposide Durvalumab Tremelimumab | Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens | Active, not recruiting | CAN | 0 |
NCT02519348 | Phase II | Tremelimumab Durvalumab | A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma | Active, not recruiting | USA | ITA | ESP | 6 |
NCT02558894 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | NLD | ESP | DEU | CAN | 1 |
NCT02626130 | Phase I | Tremelimumab | Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT02205333 | Phase Ib/II | Rituximab MEDI6469 Tremelimumab Durvalumab | A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | Terminated | USA | 0 |
NCT02868632 | Phase I | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT03557918 | Phase II | Tremelimumab | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT02485990 | Phase Ib/II | Olaparib Tremelimumab | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | Terminated | USA | 0 |
NCT06698250 | Phase II | Durvalumab Durvalumab + Tremelimumab + XL092 Tremelimumab | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) (ZENOBIA) | Not yet recruiting | USA | 0 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
NCT03007407 | Phase II | Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | Completed | USA | 0 |
NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 9 |
NCT01853618 | Phase I | Tremelimumab | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | Completed | USA | 0 |
NCT02141542 | Phase I | Tremelimumab MEDI3617 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | Completed | USA | 0 |
NCT05000710 | Phase II | Durvalumab Durvalumab + Tremelimumab Tremelimumab | Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung) | Recruiting | ISR | 0 |
NCT02453282 | Phase III | Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 6 |
NCT03026062 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Combo Versus Sequential | Active, not recruiting | USA | 0 |
NCT02535078 | Phase Ib/II | Durvalumab Tebentafusp Tremelimumab | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | Withdrawn | USA | 0 |
NCT03095274 | Phase II | Durvalumab Tremelimumab | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE) | Completed | ESP | 0 |
NCT02563925 | Phase I | Tremelimumab | Brain Irradiation and Tremelimumab in Metastatic Breast Cancer | Completed | USA | 0 |
NCT02311361 | Phase I | Durvalumab Tremelimumab | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Completed | USA | 0 |
NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
NCT02179671 | Phase II | Docetaxel + Selumetinib Gefitinib Durvalumab Osimertinib Tremelimumab | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | Completed | USA | 0 |
NCT02340975 | Phase Ib/II | Durvalumab Tremelimumab | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Completed | USA | CAN | 4 |
NCT02301130 | Phase I | Mogamulizumab Durvalumab Tremelimumab | Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | Completed | USA | 0 |
NCT02352948 | Phase III | Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) | Completed | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BGR | BEL | AUS | 9 |
NCT02319044 | Phase II | Durvalumab Tremelimumab | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | Completed | USA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 4 |
NCT02794883 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | Completed | USA | 0 |